Probucol Prevents Diabetes-Induced Retinal Neuronal Degeneration through Upregulating Nrf2

Liu, Hengwei; Luo, Yong; Zhou, Yangjie; Chen, Zhongping

doi:10.1155/2020/3862509

Cited by 7 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since we aimed to address oxidative stress and hypercholesterolemia with our drug combination, Probucol was chosen as the target co-drug to explore its combinatorial effect with Metformin. Probucol is reported to be a potentially efficacious drug to treat T2D 18 and related complications such as diabetic nephropathy 19 . However, its efficacy in combination with Metformin was unknown.…”

Section: Resultsmentioning

confidence: 99%

Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes

Guttapadu,

Korla,

et al. 2023

npj Syst Biol Appl

View full text Add to dashboard Cite

Type 2 Diabetes (T2D) is often managed with metformin as the drug of choice. While it is effective overall, many patients progress to exhibit complications. Strategic drug combinations to tackle this problem would be useful. We constructed a genome-wide protein-protein interaction network capturing a global perspective of perturbations in diabetes by integrating T2D subjects’ transcriptomic data. We computed a ‘frequently perturbed subnetwork’ in T2D that captures common perturbations across tissue types and mapped the possible effects of Metformin onto it. We then identified a set of remaining T2D perturbations and potential drug targets among them, related to oxidative stress and hypercholesterolemia. We then identified Probucol as the potential co-drug for adjunct therapy with Metformin and evaluated the efficacy of the combination in a rat model of diabetes. We find Metformin-Probucol at 5:0.5 mg/kg effective in restoring near-normal serum glucose, lipid, and cholesterol levels.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes

Guttapadu,

Korla,

et al. 2023

npj Syst Biol Appl

View full text Add to dashboard Cite

show abstract

“…It is known that probucol acts as a lipid-reducing and antioxidant agent, and it has been used in the clinical treatment and prevention of cardiovascular diseases during the past few decades. Nowadays, an increasing number of researchers are focused on the neuroprotective effect of probucol (Bueno et al, 2020; Liu et al, 2020; Mamo et al, 2018; Quispe et al, 2018). Santos and colleagues (2020) have been shown a protective effect in SH-SY5Y cells against hydroperoxide-induced cytotoxicity.…”

Section: Discussionmentioning

confidence: 99%

“…In this sense, considering specifically Mn exposure, drugs that display neuroprotection mechanisms are particularly useful. Probucol is an organic compound with antioxidant properties that has been the subject of studies in recent years demonstrating anti-inflammatory, hypolipidemic, and hypoglycemic potential (Bueno et al, 2020; Liu et al, 2020; Mooranian et al, 2018; Yamashita and Matsuzawa, 2009). Probucol prevented oxidative damage and improved cognition in experimental models of neuropathologies (Santos et al, 2020), such as Huntington’s disease (Colle et al, 2012), Alzheimer’s disease (Santos et al, 2012), and PD (Moreira et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Probucol neuroprotection against manganese-induced damage in adult Wistar rat brain slices

Del Rio Naiz,

Varela,

de Carvalho

et al. 2023

Toxicol Ind Health

View full text Add to dashboard Cite

Manganese (Mn) is an abundant element used for commercial purposes and is essential for the proper function of biological systems. Chronic exposure to high Mn concentrations causes Manganism, a Parkinson's-like neurological disorder. The pathophysiological mechanism of Manganism remains unknown; however, it involves mitochondrial dysfunction and oxidative stress. This study assessed the neuroprotective effect of probucol, a hypolipidemic agent with anti-inflammatory and antioxidant properties, on cell viability and oxidative stress in slices of the cerebral cortex and striatum from adult male Wistar rats. Brain structure slices were kept separately and incubated with manganese chloride (MnCl2) and probucol to evaluate the cell viability and oxidative parameters. Probucol prevented Mn toxicity in the cerebral cortex and striatum, as evidenced by the preservation of cell viability observed with probucol (10 and 30 μM) pre-treatment, as well as the prevention of mitochondrial complex I inhibition in the striatum (30 μM). These findings support the protective antioxidant action of probucol, attributed to its ability to prevent cell death and mitigate Mn-induced mitochondrial dysfunction.

show abstract

“… Reduce oxidative stress and inhibit neuronal apoptosis after spinal cord injury by activating the signaling pathway. [ 57 , 58 ] Procaine 5 mg in 1 mL at 25°C Local anesthetic Blockade of neurotransmission through the inhibition of sodium channels along nerve fibers. After epineural and neural diffusion, procaine reversibly and preferentially binds to active sites on the cytoplasmic aspect of neuronal voltage-gated sodium channels.…”

Section: Drug With Good Gfa (Ggfa Drug)mentioning

confidence: 99%

Characterization of Drug with Good Glass-Forming Ability Loaded Mesoporous Silica Nanoparticles and Its Impact Toward in vitro and in vivo Studies

Budiman,

Anastasya,

Handini

et al. 2024

IJN

View full text Add to dashboard Cite

Solid oral dosage forms are mostly preferred in pharmaceutical formulation development due to patient convenience, ease of product handling, high throughput, low manufacturing costs, with good physical and chemical stability. However, 70% of drug candidates have poor water solubility leading to compromised bioavailability. This phenomenon occurs because drug molecules are often absorbed after dissolving in gastrointestinal fluid. To address this limitation, delivery systems designed to improve the pharmacokinetics of drug molecules are needed to allow controlled release and target-specific delivery. Among various strategies, amorphous formulations show significantly high potential, particularly for molecules with solubility-limited dissolution rates. The ease of drug molecules to amorphized is known as their glass-forming ability (GFA). Specifically, drug molecules categorized into class III based on the Taylor classification have a low recrystallization tendency and high GFA after cooling, with substantial “glass stability” when heated. In the last decades, the application of mesoporous silica nanoparticles (MSNs) as drug delivery systems (DDS) has gained significant attention in various investigations and the pharmaceutical industry. This is attributed to the unique physicochemical properties of MSNs, including high loading capacity, recrystallization inhibition, excellent biocompatibility, and easy functionalization. Therefore, this study aimed to discuss the current state of good glass former drug loaded mesoporous silica and shows its impact on the pharmaceutical properties including dissolution and physical stability, along with in vivo study. The results show the importance of determining whether mesoporous structures are needed in amorphous formulations to improve the pharmaceutical properties of drug with a favorable GFA.

show abstract

Probucol Prevents Diabetes-Induced Retinal Neuronal Degeneration through Upregulating Nrf2

Cited by 7 publications

References 36 publications

Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes

Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes

Probucol neuroprotection against manganese-induced damage in adult Wistar rat brain slices

Characterization of Drug with Good Glass-Forming Ability Loaded Mesoporous Silica Nanoparticles and Its Impact Toward in vitro and in vivo Studies

Contact Info

Product

Resources

About